On Wed, Feb 10, 2016 at 3:37 PM, Pippa Smart <[email protected]> wrote:
> There are a few issues here and I think it is important to separate them > out. > > *$400 for course packs* > OUP allows authors who want open access to select whether they want to > restrict reuse of their article - to prevent commercial or derivative > reuses. It is the authors that select the licence they want to use - unless > their funder forces them to use a particular licence. > > The CC BY licence allows anyone (including OUP) to reuse content for > commercial reasons - i.e. to sell the articles. CC BY means that if I want > to use the articles to create a coursepack then I do not have to ask > permission - the CC BY licence allows me to do this. It also allows me to > sell my coursepacks (even if they comprise only CC BY articles). However if > I "want" to pay then there is nothing to stop someone making a charge. > [Example - someone has downloaded a series of OA CC BY articles published > in PLOS Medicine and is selling them as a book on Amazon - this is entirely > legitimate under CC BY]. > Here is OUP's wording (via RightsLink) for re-use in a pharmaceutical context for a ** CC-BY** article >>Please Contact Oxford University Press >>Please note republication of content for pharmaceutical use requires authorization from an Oxford University Press customer service representative directly. Please e-mail your request to [email protected] PMR> This states categorically that OUP forbids the re-use of CC-BY articles. I will not imply motivation to OUP - if it is deliberate then they have a case to answer. If it is not, then does it reflect a high standard of customer care (to the author, who has paid a lot of money)? This is not an isolated case - it's endemic in the Scholarly publishing industry. Elsevier calls it "The Bumpy Road" - i.e. we should feel sympathy for Elsevier in the difficult task of getting this service right. Remember that it costs a lot of money to publish CC-BY. The author's rights have been ignored. Much of the wording in Reuse Permissions is weighted towards purchase even when the reader or re-user can technically get it somewhere for free. And, of course, there is the additional ongoing problem when articles which authors have paid to have Open, are hidden behind a paywall. =========== > If an author wants to publish under a CC BY-non-commercial licence, then > they must grant OUP commercial rights - otherwise OUP could not publish > their work in this (commercial) journal. > The main problem here is exclusive, ongoing rights. Rights to publish are not the same as re-use rights which (especially in the pharma industry) can run into 7 figures for a single instance. > > > -- Peter Murray-Rust Reader in Molecular Informatics Unilever Centre, Dep. Of Chemistry University of Cambridge CB2 1EW, UK +44-1223-763069
_______________________________________________ GOAL mailing list [email protected] http://mailman.ecs.soton.ac.uk/mailman/listinfo/goal
